What is Microplate Dx?
Founded in 2017, Microplate Dx operates at the intersection of clinical diagnostics and microbiology. The company specializes in the development of rapid detection systems designed to identify antimicrobial resistance, a critical bottleneck in modern healthcare. By providing clinicians with actionable data in a fraction of the time required by traditional laboratory methods, Microplate Dx aims to improve patient outcomes and optimize antibiotic stewardship. Headquartered in the United Kingdom, the company leverages its proximity to leading academic research hubs to maintain a competitive edge in the biotechnology landscape, focusing on high-impact, scalable diagnostic tools that address one of the most pressing public health threats of the 21st century.
How much funding has Microplate Dx raised?
Microplate Dx has raised a total of $4.4M across 3 funding rounds:
Angel/Seed
$611K
Angel/Seed
$3.1M
Stock/Share Issuance
$645K
Angel/Seed (2022): $611K with participation from Deepbridge Capital and Strathclyde Inspire Entrepreneurs Fund
Angel/Seed (2023): $3.1M led by University of Strathclyde Glasgow, SIS Ventures, Scottish Enterprise, and Deepbridge Capital
Stock/Share Issuance (2025): $645K, investors not publicly disclosed
Key Investors in Microplate Dx
Deepbridge Capital
Deepbridge Capital is a private investor network that facilitates personalized portfolios for experienced investors, focusing specifically on high-growth Life Sciences and Technology companies.
Scottish Enterprise
Scottish Enterprise is the national economic development agency for Scotland, dedicated to fostering innovation and supporting the growth of high-potential businesses within the region.
SIS Ventures
SIS Ventures is an impact-led investment firm that supports mission-aligned enterprises addressing significant societal challenges, with a focus on long-term sustainable growth.
What's next for Microplate Dx?
With the successful closure of this latest funding round, Microplate Dx is well-positioned to advance its clinical validation programs and expand its commercial footprint. The strategic allocation of these funds will likely prioritize the refinement of its diagnostic hardware and the pursuit of regulatory milestones necessary for broader market adoption. As the company moves forward, the focus will shift toward establishing strategic partnerships with healthcare providers and diagnostic networks, ensuring that its AMR detection technology can be integrated into standard clinical workflows. The firm's ability to maintain a consistent growth trajectory, supported by its diverse investor base, suggests a strong outlook for its upcoming product commercialization phase.
See full Microplate Dx company page
